JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors

Keyphrases

• Macrophages 100%
• Chemotherapy Resistance 100%
• Janus Kinase 100%
• Pro-tumorigenic 100%
• Ruxolitinib 50%
• Signal Transducer and Activator of Transcription 3 50%
• Tumor Microenvironment 33%
• Tumor Factor 33%
• Breast Cancer 16%
• Tumor 16%
• Tumor Cells 16%
• Targeted Therapy 16%
• Mammary Tumor 16%
• Tumor Progression 16%
• Mammary Tumorigenesis 16%
• STAT3 Inhibitor 16%
• Tumor-associated Macrophages 16%
• Macrophage Function 16%
• Tumor Therapeutics 16%
• Myeloid Cells 16%
• In Vivo Model 16%
• Cyclooxygenase-2 16%
• Soluble Factors 16%
• Cyclooxygenase-2 Inhibitors 16%
• Janus Kinase-signal Transducer 16%
• Signal Loss 16%
• Janus Kinase Inhibitors 16%

Biochemistry, Genetics and Molecular Biology

• Macrophage 100%
• Janus Kinase 100%
• Ruxolitinib 50%
• STAT3 50%
• Cyclooxygenase 33%
• Myeloid 16%
• Macrophage Function 16%
• Carcinogenesis 16%
• Tumor Progression 16%
• Tumor-Associated Macrophage 16%

Immunology and Microbiology

• Macrophage 100%
• STAT3 50%
• Tumor-Associated Macrophage 16%
• Macrophage Function 16%
• Myeloid 16%
• Tumor Cell 16%